Lewisville, Texas (April 7, 2014) ― med fusion, an integrated, advanced laboratory and clinical trials service organization, announced today the appointment of Jon L. Hart as chief executive officer, effective March 31. This appointment is the next step in the organization’s continued drive towards becoming the clear leader in providing lab and clinical trial support to healthcare providers and biotech/pharmaceutical companies through a patient-centric support model.

 

“Jon’s distinguished track record and more than 34 years of business leadership experience in the healthcare industry make him uniquely qualified to lead our organization,” said J. Ernest Sims, board chairman, med fusion. “His experience will help med fusion continue to ramp up its services in several areas, especially in our work with precision medicine, genetic testing and molecular diagnostics.”

 

As chief executive officer, Hart will lead the company’s efforts to introduce more targeted diagnostics, reduce episode of care costs and enhance system efficiencies. He will also spearhead the company’s recent collaboration with The US Oncology Network. In 2013, physicians in The Network selected med fusion as one of their preferred diagnostic laboratories. The relationship’s aim is to advance the delivery of high-quality, precision medicine – the tailoring of medical treatment to the genetic characteristics found in each patient’s tumor – and the appropriate use of molecular diagnostics. Additionally, Hart will lead med fusion and The Network’s recent pilot program on genomic testing for non small cell lung cancer (NSCLC) patients. For the pilot, physicians in The Network will test their ability to adopt a standard molecular testing approach for all NSCLC patients. The standard is a targeted biomarker panel developed by med fusion and physicians in The Network, and the pilot’s success will demonstrate The Network’s ability to lead community oncology in precision medicine.

 

“There are a lot of exciting initiatives happening right now at med fusion and within the healthcare industry as a whole that could benefit the delivery of high-quality patient care,” said Hart. “Precision medicine is one of them. I am pleased to announce that the company recently raised a second round of funding of 71 million dollars designed to expand our capabilities in this area. I am honored to join med fusion’s top notch team and move its precision medicine initiatives forward.”

 

Previously, Hart served as president and CEO of Aurora Diagnostics, a national anatomic pathology provider based in Palm Beach Gardens, FL. Prior, Hart led a business turnaround when he was in charge of Genzyme Genetics, the esoteric laboratory division of Genzyme Corporation in Cambridge, Massachusetts. Hart has held several leadership roles throughout his career for organizations such as Arthur Young & Company in Atlanta, GA. and Quest Diagnostics in Madison, NJ.

 

Hart graduated Magna Cum Laude from Valdosta State University in Georgia with a BBA degree in Accounting. In his new role with med fusion, Hart will be based in Lewisville, Texas.

 

About med fusion

Headquartered in Lewisville, Texas, med fusion is an integrated, advanced laboratory and clinical trials service organization providing support to healthcare providers and biotech/pharmaceutical companies through a patient-centric support model. The company is working to introduce more targeted diagnostics, reduce episode of care costs and enhanced system efficiencies. Based in a 130,000 square foot facility, the company’s full service clinical laboratory includes a dedicated test development and validation team to quickly meet the needs of clients and their patients. med fusion currently has over 400 well-trained employees, and a dedicated lab staff with an average of 16 years of experience.

 

For more information please visit www.medfusionservices.com.

 

Media Contact:

Mary Olson

972-966-7137

molson@medfusionsvs.com